This project aimed to identify key proteins dysregulated by monensin and itssynthetic analog, compound 12, in the triple-negative breast cancer (TNBC) cell line MDA-MB-231. Byanalyzing the molecular changes induced by these compounds, the study sought to elucidate themechanisms underlying their cytotoxic effects on breast cancer cells. Additionally, it explored potentialdifferences in the activity and efficacy of monensin and compound 12, providing critical insights into theirdistinct biological impacts. These findings may contribute to the development of targeted therapeuticstrategies for triple-negative breast cancer, a highly aggressive and treatment-resistant subtype of breastcancer